Gearon C L, Hussain M J, Vergani D, Peakman M
Department of Immunology, King's College School of Medicine and Dentistry, London, UK.
Diabetologia. 1997 Dec;40(12):1388-95. doi: 10.1007/s001250050840.
In the therapeutic manoeuvre termed "lymphocyte vaccination", activated lymphocytes capable of transferring an autoimmune disease are instead attenuated and given in vaccine form. We have previously shown that such a therapy administered to non-obese diabetic (NOD) mice at 6 weeks of age prevents diabetes mellitus. To assess whether this therapy has potential clinical relevance, in the present study lymphocyte vaccination was applied in NOD mice in 3 weekly doses commencing in the immediate prediabetic period (age 12 weeks), when insulitis is advanced and diabetes incipient. Of 30 NOD mice receiving active vaccine (composed of attenuated lymphocytes from diabetic NOD mice) 13 (43.3%) remained non-diabetic to the age of 30 weeks, in comparison with 2 of 30 (6.7%; p < 0.01) mice receiving a control vaccine (composed of attenuated lymphocytes from non-diabetic NOD/B10 mice) and 5 of 26 (19.2%; p < 0.01) mice receiving saline carrier alone. Moreover, in an additional group of 10 NOD mice receiving active vaccine weekly between 12 and 30 weeks, 8 remained diabetes free at the end of the treatment. The most notable effect of the vaccine was that the delay in diabetes onset was accompanied by a reduction in insulitis and in some cases a complete absence of infiltrating lymphocytes at 30 weeks of age. Immunocytochemistry indicated that when present, islet infiltrating lymphocytes in non-diabetic mice that received active vaccine showed significantly reduced staining for interferon-gamma, compared with the infiltrate seen in diabetic mice receiving the control vaccine or saline. This study demonstrates that the rapid progression to diabetes typically seen in 12-week-old NOD mice can be delayed by lymphocyte vaccination, supporting the possibility that a vaccine composed of attenuated autologous peripheral blood lymphocytes could be effective in high risk first degree relatives of patients with insulin dependent diabetes mellitus.
在一种名为“淋巴细胞疫苗接种”的治疗手段中,能够引发自身免疫性疾病的活化淋巴细胞被减毒处理,并制成疫苗形式予以使用。我们之前已经表明,在6周龄时对非肥胖型糖尿病(NOD)小鼠进行这种治疗可预防糖尿病。为了评估这种治疗方法是否具有潜在的临床相关性,在本研究中,从糖尿病前期(12周龄)开始,每周给NOD小鼠接种3次淋巴细胞疫苗,此时胰岛炎已进展且糖尿病即将发生。30只接受活性疫苗(由糖尿病NOD小鼠的减毒淋巴细胞组成)的NOD小鼠中,有13只(43.3%)到30周龄时仍未患糖尿病,相比之下,30只接受对照疫苗(由非糖尿病NOD/B10小鼠的减毒淋巴细胞组成)的小鼠中有2只(6.7%;p<0.01),26只仅接受生理盐水载体的小鼠中有5只(19.2%;p<0.01)。此外,在另一组10只12至30周期间每周接受活性疫苗的NOD小鼠中,8只在治疗结束时仍未患糖尿病。该疫苗最显著的效果是,糖尿病发病延迟的同时,胰岛炎减轻,在某些情况下,30周龄时完全没有浸润淋巴细胞。免疫细胞化学表明,接受活性疫苗的非糖尿病小鼠的胰岛浸润淋巴细胞(若存在)与接受对照疫苗或生理盐水的糖尿病小鼠的浸润细胞相比,干扰素-γ染色显著减少。这项研究表明,淋巴细胞疫苗接种可以延缓12周龄NOD小鼠通常出现的糖尿病快速进展,这支持了一种由减毒自体外周血淋巴细胞组成的疫苗可能对胰岛素依赖型糖尿病患者的高危一级亲属有效的可能性。